Moksifloksacin Stada (Moxifloxacin)

Moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes that are essential for DNA replication and transcription. By blocking these targets, the drug prevents bacterial DNA from unwinding and resealing, leading to bacterial cell death and eradication of the infection.

The prescribed dose of Moksifloksacin Stada is determined by the treating physician based on the type and severity of the infection, patient age, renal and hepatic function, and other clinical considerations. Dosage regimens are individualized and should follow the prescriber's instructions.

Safety data for moxifloxacin in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team will then respond with pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Moxifloxacin offers a broader spectrum of activity against atypical and Gram‑positive pathogens compared with some older fluoroquinolones such as ciprofloxacin. It also provides once‑daily dosing for many indications, which can improve patient adherence. However, safety considerations such as tendon toxicity and QT prolongation are similar across the class, so risk‑benefit assessment remains essential.

Moksifloksacin Stada should be stored at ambient temperature below 25 °C, in its original packaging, protected from moisture and direct light. Keep the product out of reach of children and avoid storing it in humid environments such as bathrooms.

The medication is taken orally, usually as a tablet, with a full glass of water. It can be taken with or without food, but patients should follow the specific instructions provided by their prescriber to ensure optimal absorption.

Serious adverse events include tendon rupture or inflammation, QT interval prolongation that may lead to cardiac arrhythmias, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, peripheral neuropathy, and significant liver enzyme elevations. Patients should seek immediate medical attention if they experience sudden joint pain, palpitations, severe rash, or persistent diarrhea.

Moksifloksacin Stada is contraindicated in individuals with a known hypersensitivity to moxifloxacin or other fluoroquinolones. It should also be avoided in patients with a history of tendon disorders related to fluoroquinolone use, those with uncontrolled arrhythmias, and, unless clearly justified, in pregnant or breastfeeding women due to limited safety data.